Leukemia Clinical Trial
Official title:
A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Verified date | June 2023 |
Source | Eastern Cooperative Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining more than one drug or combining monoclonal antibody with chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia. PURPOSE: Randomized phase II trial to compare the effectiveness of three treatment regimens in treating patients who have relapsed or refractory acute myelogenous leukemia.
Status | Completed |
Enrollment | 0 |
Est. completion date | June 2007 |
Est. primary completion date | October 2005 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | DISEASE CHARACTERISTICS: - Histologically proven acute myelogenous leukemia of one of the following types: - Acute myeloblastic leukemia (FAB type M0, M1, or M2) - Acute promyelocytic leukemia (FAB type M3) allowed if ineligible for an ECOG M3 protocol or if no tretinoin or arsenic trioxide therapy is planned - Acute myelomonocytic leukemia (FAB type M4) - Acute monocytic leukemia (FAB type M5) - Acute erythroleukemia (FAB type M6) - Acute megakaryocytic leukemia (FAB type M7) - Must meet 1 of the following criteria: - Relapse less than 6 months after first complete remission (CR) - Relapse 6-12 months after first CR - Refractory to conventional initial induction chemotherapy (no more than 2 courses) or first reinduction (no more than 1 course) - Must have marrow documentation of residual leukemia after chemotherapy (for at least 2 weeks duration) - Second or greater relapse - No relapse greater than 1 year after achieving first CR - Blast cells must be CD33 positive - Prior CNS leukemia allowed if there is currently documentation of no CNS involvement on CSF examination (i.e., negative CSF by lumbar puncture) PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - See Disease Characteristics Hepatic: - Bilirubin no greater than 2.0 mg/dL* - SGOT less than 2 times upper limit of normal* NOTE: *Unless due to leukemia infiltration Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - See Chemotherapy - No myocardial infarction within the past 3 months - No significant congestive heart failure - No significant cardiac arrhythmia - Cardiac ejection fraction normal by MUGA scan or echocardiogram - Resting ejection fraction at least 50% or at least 5% increase with exercise - Shortening fraction at least 24% or normal by echocardiogram Other: - Not pregnant or nursing - Fertile patients must use effective contraception - No concurrent organ damage or other medical problems that would precludestudy therapy - No concurrent evidence (including positive blood or deep tissue cultures or stains) of invasive fungal infection - No hypersensitivity to ingredients of gemtuzumab ozogamicin or daunorubicin liposomal - No other active tumor that would interfere with study therapy or increase risk PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior gemtuzumab ozogamicin Chemotherapy: - See Disease Characteristics - See Biologic therapy - No prior daunorubicin liposomal or topotecan - Prior doxorubicin (no greater than 300 mg/m2), daunorubicin (no greater than 300 mg/m2), idarubicin (no greater than 100 mg/m2), or mitoxantrone (no greater than 100 mg/m2) allowed if left ventricular function is adequate - At least 4 weeks since prior chemotherapy except patients who are refractory to conventional initial induction chemotherapy - Prior hydroxyurea allowed within 4 weeks prior to beginning study - Hydroxyurea must be discontinued at least 24 hours prior to beginning study Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy except patients who are refractory to conventional initial induction chemotherapy Surgery: - Not specified |
Country | Name | City | State |
---|---|---|---|
Puerto Rico | MBCCOP - San Juan | San Juan | |
Puerto Rico | Veterans Affairs Medical Center - San Juan | San Juan | |
South Africa | Pretoria Academic Hospitals | Pretoria | |
United States | CCOP - Ann Arbor Regional | Ann Arbor | Michigan |
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | New England Medical Center Hospital | Boston | Massachusetts |
United States | Albert Einstein Comprehensive Cancer Center | Bronx | New York |
United States | MBCCOP-Our Lady of Mercy Cancer Center | Bronx | New York |
United States | Veterans Affairs Medical Center - Brooklyn | Brooklyn | New York |
United States | CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa |
United States | Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago | Illinois |
United States | Veterans Affairs Medical Center - Lakeside Chicago | Chicago | Illinois |
United States | Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio |
United States | Ireland Cancer Center | Cleveland | Ohio |
United States | CCOP - Columbus | Columbus | Ohio |
United States | CCOP - Central Illinois | Decatur | Illinois |
United States | CCOP - Colorado Cancer Research Program, Inc. | Denver | Colorado |
United States | CCOP - Iowa Oncology Research Association | Des Moines | Iowa |
United States | Cancer Center and Beckman Research Institute, City of Hope | Duarte | California |
United States | CCOP - Duluth | Duluth | Minnesota |
United States | Veterans Affairs Medical Center - East Orange | East Orange | New Jersey |
United States | CCOP - Evanston | Evanston | Illinois |
United States | CCOP - Merit Care Hospital | Fargo | North Dakota |
United States | Veterans Affairs Medical Center - Gainsville | Gainesville | Florida |
United States | CCOP - Northern New Jersey | Hackensack | New Jersey |
United States | Indiana University Cancer Center | Indianapolis | Indiana |
United States | Veterans Affairs Medical Center - Indianapolis (Roudebush) | Indianapolis | Indiana |
United States | Holden Comprehensive Cancer Center at The University of Iowa | Iowa City | Iowa |
United States | CCOP - Kalamazoo | Kalamazoo | Michigan |
United States | CCOP - Southern Nevada Cancer Research Foundation | Las Vegas | Nevada |
United States | University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin |
United States | Veterans Affairs Medical Center - Madison | Madison | Wisconsin |
United States | CCOP - Marshfield Medical Research and Education Foundation | Marshfield | Wisconsin |
United States | Veterans Affairs Medical Center - Miami | Miami | Florida |
United States | University of Minnesota Cancer Center | Minneapolis | Minnesota |
United States | Veterans Affairs Medical Center - Minneapolis | Minneapolis | Minnesota |
United States | Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | CCOP - Ochsner | New Orleans | Louisiana |
United States | MBCCOP - LSU Health Sciences Center | New Orleans | Louisiana |
United States | NYU School of Medicine's Kaplan Comprehensive Cancer Center | New York | New York |
United States | Veterans Affairs Medical Center - New York | New York | New York |
United States | CCOP - Missouri Valley Cancer Consortium | Omaha | Nebraska |
United States | Veterans Affairs Medical Center - Omaha | Omaha | Nebraska |
United States | Veterans Affairs Medical Center - Palo Alto | Palo Alto | California |
United States | CCOP - Illinois Oncology Research Association | Peoria | Illinois |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Hahnemann University Hospital | Philadelphia | Pennsylvania |
United States | Kimmel Cancer Center of Thomas Jefferson University - Philadelphia | Philadelphia | Pennsylvania |
United States | University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania |
United States | University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania |
United States | Veterans Affairs Medical Center - Pittsburgh | Pittsburgh | Pennsylvania |
United States | Mayo Clinic Cancer Center | Rochester | Minnesota |
United States | University of Rochester Cancer Center | Rochester | New York |
United States | CCOP - Metro-Minnesota | Saint Louis Park | Minnesota |
United States | CCOP - Scottsdale Oncology Program | Scottsdale | Arizona |
United States | CCOP - Sioux Community Cancer Consortium | Sioux Falls | South Dakota |
United States | Stanford University Medical Center | Stanford | California |
United States | H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida |
United States | Veterans Affairs Medical Center - Tampa (Haley) | Tampa | Florida |
United States | CCOP - Toledo Community Hospital Oncology Program | Toledo | Ohio |
United States | CCOP - Oklahoma | Tulsa | Oklahoma |
United States | CCOP - Carle Cancer Center | Urbana | Illinois |
United States | CCOP - Christiana Care Health Services | Wilmington | Delaware |
United States | CCOP - MainLine Health | Wynnewood | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Eastern Cooperative Oncology Group | National Cancer Institute (NCI) |
United States, Puerto Rico, South Africa,
Litzow MR, Goloubeva O, Rowe J, et al.: A randomized phase II trial of gemtuzumab ozogamicin vs. liposomal daunorubicin vs. cyclophosphamide plus topotecan, each combined with intermediate dose Ara-C for the treatment of patients with relapsed or refracto
Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS; Eastern Cooperative Oncology Group Leukemia Committee. Failure of three novel regimens to improve outcome for patients with relapsed or refr — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |